Development of Patient-Derived Colorectal Cancer Xenograft and Organoid Models with Acquired Resistance to KRAS G12C Inhibitors

被引：0
|
作者：
Hua, L. [1 ]
Zheng, J. [2 ]
Wang, J. [1 ]
Shang, L. [3 ]
Qian, W. [4 ]
Sun, Y. [3 ]
Bourre, L. [5 ]
Wang, J. [1 ]
机构：
[1] Crown Biosci Inc, Canc Pharmacol, San Diego, CA USA
[2] Crown Biosci Inc, Oncol In Vivo, San Diego, CA USA
[3] Crown Biosci Inc, In Vivo, San Diego, CA USA
[4] Crown Biosci Inc, Data Sci & Bioinformat, San Diego, CA USA
[5] Crown Biosci Inc, Res & Innovat, San Diego, CA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114789
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB262
引用
收藏
页码：S104 / S105
页数：2
相关论文
共 50 条
  • [1] Establishment of KRAS G12C mutant patient-derived xenograft (PDX) models for pre-clinical evaluation of KRAS G12C targeted anticancer therapy.
    Shi, Wenting
    Tang, Xuzhen
    Zhang, Jingying
    Kuang, Xinhong
    Zhang, Yan
    Wang, Jingjing
    Gu, Qingyang
    Ji, Qunsheng
    CANCER RESEARCH, 2021, 81 (13)
  • [2] KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer
    Xiao, Annie
    Fakih, Marwan
    CLINICAL COLORECTAL CANCER, 2024, 23 (03) : 199 - 206
  • [3] Overcoming resistance to KRAS G12C inhibitors in lung cancer
    Ambrogio, Chiara
    CANCER SCIENCE, 2023, 114 : 987 - 987
  • [4] Mechanisms of Resistance to KRAS G12C Inhibitors
    Ambrogio, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S96 - S96
  • [5] Mechanisms of acquired resistance to KRAS G12C inhibition in cancer.
    Awad, Mark
    Liu, Shengwu
    Arbour, Kathryn
    Zhu, Viola
    Johnson, Melissa
    Heist, Rebecca
    Patil, Tejas
    Riely, Gregory
    Jacobson, Joseph
    Dilly, Julien
    Yang, Xiaoping
    Persky, Nicole
    Root, David
    Sholl, Lynette
    Lim, Lee
    Garg, Kavita
    Li, Mark
    Engstrom, Lars
    Waters, Laura
    Lawson, J. David
    Olson, Peter
    Christensen, James
    Lito, Piro
    Ou, Sai-Hong Inatius
    Janne, Pasi
    Aguirre, Andrew
    CANCER RESEARCH, 2021, 81 (13)
  • [6] Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
    Matsubara, Hiroyuki
    Miyoshi, Hiroyuki
    Kakizaki, Fumihiko
    Morimoto, Tomonori
    Kawada, Kenji
    Yamamoto, Takehito
    Obama, Kazutaka
    Sakai, Yoshiharu
    Taketo, Makoto Mark
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (04) : 529 - 538
  • [7] Overcoming adaptive resistance to KRAS G12C inhibitors
    Adachi, Yuta
    Niitsu, Hiroaki
    Yamaguchi, Rui
    Ebi, Hiromichi
    CANCER SCIENCE, 2024, 115 : 110 - 110
  • [8] EMT is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C mutant NSCLC
    Adachi, Yuta
    Ito, Kentaro
    Kimura, Ryo
    Yamaguchi, Rui
    Ebi, Hiromichi
    ANNALS OF ONCOLOGY, 2021, 32 : S307 - S307
  • [9] KRAS G12C inhibitors in metastatic colorectal cancer: a tale of two targets
    Martinez-Perez, Julia
    Valladares-Ayerbes, Manuel
    TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 9
  • [10] Progress of KRAS G12C inhibitors in the treatment of refractory colorectal cancer and strategies for drug resistance response
    Yang, Peiyuan
    Li, Yongchao
    INVESTIGATIONAL NEW DRUGS, 2025, : 357 - 364
12345